Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Gross Profit: 2019-2024

Historic Gross Profit for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $61,000.

  • Lyell Immunopharma's Gross Profit fell 55.88% to $15,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $41,000, marking a year-over-year decrease of 34.92%. This contributed to the annual value of $61,000 for FY2024, which is 53.08% down from last year.
  • Per Lyell Immunopharma's latest filing, its Gross Profit stood at $61,000 for FY2024, which was down 53.08% from $130,000 recorded in FY2023.
  • In the past 5 years, Lyell Immunopharma's Gross Profit registered a high of $84.7 million during FY2022, and its lowest value of $61,000 during FY2024.
  • Its 3-year average for Gross Profit is $28.3 million, with a median of $130,000 in 2023.
  • As far as peak fluctuations go, Lyell Immunopharma's Gross Profit surged by 1,080.52% in 2020, and later plummeted by 99.85% in 2023.
  • Lyell Immunopharma's Gross Profit (Yearly) stood at $7.8 million in 2020, then skyrocketed by 37.31% to $10.7 million in 2021, then soared by 695.15% to $84.7 million in 2022, then tumbled by 99.85% to $130,000 in 2023, then slumped by 53.08% to $61,000 in 2024.